Key facts
- It has raised $14.5M; the latest was Later Stage VC in Jan 2025.
- Notable investors include Changsha Chang Xin Investment Management, Guangdong Hengjian Investment, Huaying Investment, Hunan Heng Chang Pharmaceutical Group, Hygeia Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Yineng Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Yineng Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yineng Pharma
Developer of full-cycle traditional Chinese medicine drug designed to accelerate TCM drug research and development and lower the costs. The company offers international leading databases and 20 traditional Chinese processing and formulation platforms for granules, pills, capsules and modern formulations, thereby providing pharmaceutical companies with TCM drug research and development, registration, industrialized production and marketing services.
- Sector
- Healthcare
- HQ
- Changsha, China
- Founded
- 2009
- Employees
- 400
- Website
- hnynswyy.cn/
- Ownership
- Privately Held (backing)
Yineng Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yineng Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yineng Pharma in its N-PORT filings yet. We sweep new filings monthly.